Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fosinopril Sodium

FDA-approved product (tablet, oral), marketed as Fosinopril Sodium, Monopril.

Registered studies
21
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fosinopril Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Heart failure
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli42.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis47.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fosinopril Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fosinopril Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions

    NCT00777972 · start 2003-03

    Registered record
    Registry ID
    NCT00777972
    Conditions
    Healthy
    Interventions
    Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-03
    Completion
    2003-04
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions

    NCT00778713 · start 2003-03

    Registered record
    Registry ID
    NCT00778713
    Conditions
    Healthy
    Interventions
    Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-03
    Completion
    2003-04
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions

    NCT00776334 · start 2002-10

    Registered record
    Registry ID
    NCT00776334
    Conditions
    Healthy
    Interventions
    Fosinopril 40mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-10
    Completion
    2002-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFosinopril 40mg Tablets
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions

    NCT00776672 · start 2002-10

    Registered record
    Registry ID
    NCT00776672
    Conditions
    Healthy
    Interventions
    Fosinopril 40mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-10
    Completion
    2002-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFosinopril 40mg Tablets
    PhaseNot applicable
    Registry statusCompleted

  • ACE Inhibition and Novel Cardiovascular Risk Factors

    NCT00051389 · start 2002-02

    Registered record
    Registry ID
    NCT00051389
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension
    Interventions
    Fosinopril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-02
    Completion
    2007-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension
    InterventionFosinopril
    PhasePhase 2
    Registry statusCompleted

  • Prevention of Renal and Vascular Endstage Disease Intervention Trial

    NCT03073018 · start 1998-04

    Registered record
    Registry ID
    NCT03073018
    Conditions
    Microalbuminuria; Cardiovascular Diseases; Renal Disease
    Interventions
    Fosinopril; Pravastatin; Fosinopril Placebo; Pravastatin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-04
    Completion
    2003-11
    Enrolment
    864

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicroalbuminuria; Cardiovascular Diseases; Renal Disease
    InterventionFosinopril; Pravastatin; Fosinopril Placebo; Pravastatin Placebo
    PhasePhase 3
    Registry statusCompleted